Redeye argues that AVTECH has delivered another strong report with sales growth of 37% y/y, which wa...
Redeye lowers its estimates on the back of I-Tech’s second quarter, which showed a surprising slowdo...
* A quarter centred on preparations * Orviglance FDA submission around the corner * Fair value range...
Redeye provides an in-depth review of Acarix’s Q2 report and related events during and after the qua...
* Gross margin at 45% (40%) * SaaS supports margins and outlook * Trading at ~11-9x EV/EBITA for '26...
* Q2 sales +3% and EBITDA +4% vs. ABGSCe * We raise EBITDA by 1-4% and EBIT by 4-8% for '26e-'27e * ...
Nettoomsättningen för det andra kvartalet uppgick till 6,6 MEURO (10,2), vilket motsvarade en minskn...
Acuvi redovisade ökad nettoomsättning och EBIT i det andra kvartalet.
Redeye provides a research update following the Q2 report recently published by Initiator Pharma.
* Sales SEK 6.5m, EBIT SEK -16m (vs. ABGSCe 11m and -12m) * No machine deliveries in the quarter (in...
Mendus’s Q225 results reflect a period of progress across the pipeline.
Solteq’s Q2 result was below our expectations. Retail & Commerce was decent, while Utilities remaine...
* Sales -39% vs. ABGSCe, EBIT SEK 5m vs. ABGSCe 16m * Weak Q2 due to inventory build-up following st...
Redeye comments on I-Tech’s Q2 figures that missed our expectations, driven by weaker sales.
Redeye comments on Sleep Cycle’s Q2 report, which was broadly in line with expectations.
Redeye notes that InfraCom’s Q2 2025 report was below expectations for sales (-9%) and EBITDA (-12%)...
Redeye updates on Better Collective after Q2 where results were slightly below our forecasts while t...
Redeye updates its estimates following Surgical Science’s Q2 2025 report, which aligned with the com...
Redeye comments on Oncopeptides’ 2nd quarter report, which saw significant sales progress in the cor...
* Minor estimate revisions * On track to reach 1m paying users in '25e * Maintain fair value range o...